As the SVP Commercial of Beaconcure, Sean is responsible for overseeing all commercial activities within the organization, including Sales, Marketing, and Customer Success. With almost 20 years in business development, including 9 years dedicated to life sciences, Sean brings a wealth of experience to drive growth and customer satisfaction across the Beaconcure organization. Sean has supported organizations of all sizes, from start-ups such as Medable to industry leaders IBM and PPD, a Thermo Fisher company.

Sean has demonstrated a passion for business development and honed his skills in building lasting client and industry relationships. When he’s not advocating for Beaconcure’s solution to transform the clinical trial data validation process, you can find him spending time with his wife and son, on a yoga mat, or rolling around on the floor wrestling his Bernedoodle Eva.

Sean has a Bachelor of Science degree in Biology from the University of North Carolina at Wilmington.

Ilan Carmeli brings deep expertise in user-centric machine learning-based software to his leadership at Beaconcure. Leveraging his background in designing innovative products that place customer needs first, Ilan now focuses on creating elegant AI products for statistical clinical analysis. His passion for advancing clinical trials through developing cutting-edge yet intuitive AI solutions aligns closely with Beaconcure's commitment to shaping a responsible and human-centric approach to emerging technology.

Beyond Ilan’s contributions at Beaconcure, he actively pays his experience forward by mentoring aspiring entrepreneurs and students in Israel's technology community. He holds a BSc in Information Management Engineering from Ben Gurion University. 

Through Ilan’s diverse background spanning machine learning R&D, product innovation, and mentorship initiatives, he brings a well-rounded, user-focused perspective to AI advancement.

Luisa Freitas dos Santos, PhD, FREng, CEng, FIChemE, is Vice President Global Head Clinical Supply Chain at GSK. She leads a multidisciplinary team across the UK, USA, Belgium, Italy, and Singapore responsible for GMP clinical manufacturing operations and Clinical Trial Supply management for GSK's extensive medicine and vaccine portfolios. Dr Freitas dos Santos has extensive pharmaceutical drug development experience, and over her 28-year tenure at GSK she has made exceptional contributions to the integration of bio/chemical engineering, pharmaceutical and data sciences, leading to substantial improvements in clinical manufacturing and trial execution. Her interdisciplinary approach and direct sustained contributions have been instrumental in the successful approval of 26 novel medicines and vaccines in a broad range of therapeutic areas including respiratory, infectious diseases and oncology, impacting millions of patients globally.

She led the deployment of new manufacturing technologies for increasingly complex drug modalities, such as oligonucleotides and antibody drug conjugates; and the digitalization of GSK’s clinical supply chain enabling rapid translation of complex clinical study designs into delivery of improved solutions for patients.

Dr Freitas dos Santos holds a degree in Process Engineering, and PhD and Post Doc in Chemical Engineering from Imperial College London. She co-founded a spin-out company based on her PhD research, gaining substantial experience in technology development and transfer. She has published over 50 peer-reviewed research papers, presented at hundreds of conferences, and received numerous awards. She is a Fellow of the UK Institution of Chemical Engineers, and Fellow of the Royal Academy of Engineering.

As deputy director of MUSC Hollings Cancer Center, William Hawkins, MD, focuses on strengthening translational research and increasing clinical trials across South Carolina. With a longstanding commitment to leadership, patient care, education and research, Hawkins has expertise in investigating pancreatic cancer. He is also a professor in the Department of Surgery at MUSC and in the Division of Surgical Oncology.

Marta joined our company in 1998 as a Clinical Research Associate (CRA) in Spain. Earlier in her career, she was a CRA at Phidea International and a Laboratory Fellow, Neuroscience, Navarra University in Pamplona, Spain. After different country roles in both Spain and Netherlands, Marta served as Clinical Research Director (CRD) for Spain and Portugal; Head of GCTO’s mid-Europe Region and subsequent Europe-2 Region covering Central & Eastern Europe, Middle East & Africa.

From 2017 to 2022 she had different GCTO HQ roles including Quality & continuous improvement where she was in charge of strengthening clinical QMS and had a leadership role in regulatory inspections including site, sponsor and third-party preparation and training. Over the years, she led several transformation efforts in GCTO operating model, Global trade compliance roll out, Brexit or EU CTR implementation.

Since May 2022, Marta is leading Global Clinical Supply group under DSCS and is accountable for managing the end-to-end& clinical supply chain across all MRL portfolios to enable the execution of any clinical trial using a Merck asset. In this role, Marta led a transformation journey to modernize GCS operations, strengthening Operational excellence and Continuous improvement culture, with special focus in upskilling and developing talent while increasing agility and speed to better serve the current needs of MRL clinical trials.

Marta received a Bachelor of Science degree in biochemistry and molecular biology from UAM University in Madrid, Spain. She also holds a Master of Science degree in Research & Development from Navarra University and has completed diverse business leadership programs.

Dr Kenneth Waterman received his B.S. degree with honors in Chemistry from UCLA, his Ph.D. in Physical Organic Chemistry from UC Berkeley and conducted post-doctoral studies in physical and photo-chemistry as an NIH Research Fellow at Columbia University. Dr Waterman’s distinguished career includes 12 years as a scientist at Polaroid working to develop imaging products, and 13 years as a Research Fellow at Pfizer working on drug stability, drug delivery, biopharmaceutics and prodrugs, before founding FreeThink Technologies, a laboratory and software company with unique expertise in stability, packaging and formulations. In addition, FreeThink produces and licenses its advanced accelerated stability software, ASAPprime®. He is an AAPS Fellow and the author of over 75 publications/patents.

Mario Torchia gained 15 years of experience in the tech industry, working in multinational companies such as Dassault Systèmes and Siemens. Most recently he led the Sales Strategy as Delmia Geo Leader for South Europe at Dassault Systèmes, actively supporting customers in their business transformation journey.  Previously, he spent four years in Sao Paulo, managing the Brazilian branch of Hyla Soft, a global IT company that provides technology solutions to improve productivity and efficiency within Manufacturing Engineering, Manufacturing Operations and Sales and Operations Planning processes.  Holding a degree in Computer Engineering, Torchia is passionate about technology, innovation, arts, and water sports. He is currently the Chief Operating Officer (COO) at InSilicoTrials, having previously led the sales and marketing team. Torchia leverages his extensive experience with large and medium-sized companies, strategic market vision, and skills in helping startups expand in international markets.

Matt Holms is the VP of Sales responsible for overseeing Patient Engagement & Recruitment Solutions at Citeline. He has spent 24 years in the Life Science industry, holding various commercial & executive leadership roles, dedicated to driving innovative technology solutions that enhance clinical research across a diverse spectrum of eClinical technology, Patient Recruitment/RWD, and Sponsor organizations. Beyond his professional endeavors, he is passionate about patient access and awareness of clinical research opportunities, having personally experienced life-changing results and benefits as a clinical research study participant.

Dr. Abhijeet Maurya is a pharmaceutical scientist with a diverse background in product development and process optimization. Currently serving as a Process Development Principal Scientist at Amgen, he is an integral part of the synthetics prepivotal team, focusing on enabling technologies to overcome challenges associated with the dosing properties of complex drug molecules. Dr. Maurya has held key positions at Adare Pharma Solutions and Bend Research and began his career as an ORISE Post-doctoral fellow at the U.S. FDA's Office of Pharmaceutical Quality. He is a member of the Editorial Advisory Board of AAPS PharmSciTech and has published numerous articles and book chapters.

Mrs. Spaziani has over 25 years of experience within the clinical research industry on both the sponsor and CRO side. Starting as a Clinical Research Associate, Mrs. Spaziani was rapidly promoted to regional and global clinical management positions. Mrs. Spaziani has extensive and diverse experience with study feasibility and study start-up through study closure and archival including protocol and CRF development, site selection, Investigator Meeting management, clinical study site monitoring, vendor management, and collaborating on clinical study reports and IND Updates. Mrs. Spaziani has supported global clinical study management by utilizing data to accurately forecast recruitment projections, select quality enrolling sites, and meet planned recruitment commitments. She has spent the last 15 years focused on study start-up.

Dr LeBel is the founder of CPL Bioconsulting, LLC., a consulting firm that assists biotech clients with their corporate and drug development strategies. He also serves as Chief Executive Officer for pacDNA, Inc., a Northeastern University spinout focused on improving the potential of oligonucleotide therapeutics. From 2018-2023 Dr LeBel served as Chief Development Officer for Frequency Therapeutics, Inc., a development stage biotech company focused on treatments for sensorineural hearing loss. Before that he was Entrepreneur-in-Residence and Affiliate Associate Professor in the Bouvé College of Health Sciences at Northeastern University, where he assisted faculty, students, and alumni with forming and guiding their startups. Prior to that Dr LeBel was the Chief Scientific Officer at Otonomy, Inc., from 2009-2017 where he was responsible for all R&D activities focused on discovery and development of biotherapeutics to treat conditions of the ear. Before that he was President and CEO at Akesis Pharmaceuticals, Inc., a public metabolic disease firm. Additionally, he held numerous R&D management positions during a 14-year tenure at Amgen Inc. Prior to that he held pharmacology/toxicology positions at Alkermes, Inc. and Arthur D. Little, Inc. Dr LeBel obtained a BS in Chemistry from the University of Detroit, a PhD in Biomedical Sciences/Toxicology from Northeastern University, and he was a NIEHS postdoctoral fellow in Community and Environmental Medicine at the University of California, Irvine.

Dr Colin McKinlay is the senior director of chemistry and delivery technologies at Nutcracker Therapeutics. He has significant expertise in nucleic acid delivery through his doctoral research at Stanford University with professors Paul Wender and Robert Waymouth. Dr McKinlay’s research involved preparation of synthetic delivery vehicles through organocatalytic ring-opening polymerization; their characterization; and in vitro and in vivo evaluation for the delivery of DNA, RNA, and other biological macromolecules. He holds over five patents and has nine peer-reviewed publications on chemical delivery technologies. Dr McKinlay has led the delivery efforts at Nutcracker Therapeutics since 2018, including the establishment of its unique peptoid-based Nutshell® delivery platform.